Prophylaxis of migraine, transformed migraine, and cluster headache with topiramate

Headache

Volumn 42, Issue 8, 2002, Pages 796-803

  Mathew, Ninan T ^a   Kailasam, Jayasree ^a   Meadors, Lori ^a  

^a Houston Headache Clinic   (United States)

Author keywords

Episodic; Headache; Migraine; Monotherapy; Prophylaxis; Topiramate; Transformed

Indexed keywords

ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOOXYGENASE 2 INHIBITOR; METHYSERGIDE; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL RESEARCH; CLUSTER HEADACHE; COGNITIVE DEFECT; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EVALUATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; PARESTHESIA; PRIORITY JOURNAL; RATING SCALE; RECURRENCE RISK; TABLET FORMULATION; TREATMENT OUTCOME; VERTIGO;

ADULT; AGED; ANTICONVULSANTS; CHRONIC DISEASE; CLUSTER HEADACHE; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0036754793     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.2002.02183.x     Document Type: Article

References (30)

1. Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population: A prevalence study. J Clin Epidemiol. 1991;44:1147-1157.
2. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States: Relation to age, income, race, and other sociodemographic factors. J Am Med Assoc. 1992;267:64-69.
3. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: Disability and economic costs. Arch Intern Med. 1999;159:813-818.
4. Stewart WF, Shechter A, Rasmussen BK. Migraine prevalence. A review of population-based studies. Neurology. 1994;44:S17-S23.
5. Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: Results from the American Migraine Study. Headache. 1998;38:87-96.
6. Silberstein SD. Migraine: diagnosis and treatment. In: Lipton RB, Goadsby PJ, eds. Headache in Clinical Practice. Oxford, UK: Isis Medical Media; 1998: 61-90.
7. Ramadan NM, Silberstein SD, Freitag FG, Gilbert TT, Frishberg BM. Evidence-based Guidelines for Migraine Headache in the Primary Care Setting: Pharmacological Management for Prevention of Migraine. U.S. Headache Consortium. 2001:1-55. Available at: http://www.aan.com/professionals/practice/pdfs/g10090. pdf. Accessed 2002.
8. Duke University Center for Clinical Health Policy Research. Drug Treatments for the Prevention of Migraine Headache. Publication No. 290-94-2025 (Technical Review 2.3). Springfield, VA: U.S. Department of Commerce; 1999.
9. Krusz JC, Scott V. Topiramate in the treatment of chronic migraine and other headaches. Headache. 2000;39:363.
10. Shuaib A, Ahmed F, Muratoglu M, Kochanski P. Topiramate in migraine prophylaxis: A pilot study. Cephalalgia. 1999;19:379-380.
11. Storey JR, Calder CS, Potter DL. Role of topiramate for refractory migraine prophylaxis: A retrospective pilot study. Ann Neurol. 2000;46:495.
12. Von Seggern RL, Mannix LK, Adelman JU. Efficacy of topiramate in migraine prophylaxis: A retrospective chart analysis. Neurology. 2000;54:A267-A268.
13. Wheeler SD, Carrazana EJ. Topiramate-treated cluster headache. Neurology. 1999;53:234-236.
14. Edwards KR, Gkantz MJ, Shea P, Norton JA, Cross N. Topiramate for migraine prophylaxis: A double-blind, randomized, placebo-controlled study. Headache. 2000;40:407.
15. Potter DL, Hart DE, Calder CS, Storey JR. A double-blind, randomized, placebo-controlled, parallel study to determine the efficacy of topiramate in the prophylactic treatment of migraine. Neurology. 2000;54(7 suppl 3):A15.
16. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41:S3-S9.
17. Mathew NT, Reuveni U, Perez F. Transformed or evolutive migraine. Headache. 1987;27:102-106.
18. Mathew NT. Transformed migraine, analgesic rebound, and other chronic daily headaches. Neurol Clin. 1997;15:167-186.
19. Baldrati A, Bini L, D'Alessandro R, et al. Analysis of outcome predictors of migraine towards chronicity. Cephalalgia. 1985;5(suppl 2):195-199.
20. Pradalier A, Serratrice G, Collard M, et al. Long-acting propranolol in migraine prophylaxis: Results of a double-blind, placebo-controlled study. Cephalalgia. 1989;9:247-253.
21. Sargent J, Solbach P, Damasio H, et al. A comparison of naproxen sodium to propranolol hydrochloride and a placebo control for the prophylaxis of migraine headache. Headache. 1985;25:320-324.
22. Borgesen SE, Nielsen JL, Moller CE. Prophylactic treatment of migraine with propranolol. A clinical trial. Acta Neurol Scand. 1974;50:651-656.
23. Kangasniemi P, Andersen AR, Andersson PG, et al. Classic migraine: Effective prophylaxis with metoprolol. Cephalalgia. 1987;7:231-238.
24. Tomkins GE, Jackson JL, O'Malley PG, Balden E, Santoro JE. Treatment of chronic headache with anti-depressants: A meta-analysis. Am J Med. 2001;111:54-63.
25. Gardner DM, Lynd LD. Sumatriptan contraindications and the serotonin syndrome. Ann Pharmacother. 1998;32:33-38.
26. Mathew NT, Tietjen GE, Lucker C. Serotonin syndrome complicating migraine pharmacotherapy. Cephalalgia. 1996;16:323-327.
27. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol. 1995;52:281-286.
28. Klapper J. Divalproex sodium in migraine prophylaxis: A dose-controlled study. Cephalalgia. 1997;17:103-108.
29. Freitag FG, Diamond S, Diamond ML, Urban GJ. Divalproex in the long-term treatment of chronic daily headache. Headache. 2001;41:271-278.
30. Hering R, Kuritzky A. Sodium valproate in the treatment of cluster headache: An open clinical trial. Cephalalgia. 1989;9:195-198.